2013;73:6900-12. SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/ MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 238 Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple -negative breast cancer. Cancer Res.2015;75(suppl 15): Abstr. # 2859. Emens L, Adams S, Loi S, et al. A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple -negative breast cancer (mTNBC). Proc 38th SABCS.